Suzhou Generic Medical Technology
New type of medicine that is based on personalized medicine and is developing rapidly with the advancement of genomic sequencing technology and the cross-application of bioinformatics and big data science.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor investor investor | €0.0 | round | |
* | N/A | CNY20.0m Valuation: CNY500m | Series B |
| Total Funding | 000k | ||
Related Content
Regend operates in the regenerative medicine sector, focusing on the research, development, and commercialization of cell therapy and health diagnostic products. The company serves clients in the healthcare industry, including patients and medical professionals, by providing innovative solutions for lung regeneration and other medical conditions. Regend's business model revolves around building an industrial chain that encompasses basic research, pre-clinical development, clinical trials, and product commercialization. Revenue is generated through the development and sale of regenerative medicine products, supported by a robust R&D infrastructure and compliance with international quality standards. The company is committed to prioritizing the life and health of consumers and patients, leveraging scientific advancements to transform healthcare outcomes.
Keywords: regenerative medicine, cell therapy, health diagnostics, lung regeneration, clinical trials, commercialization, healthcare, R&D, ISO9001, life science.